ResearchPUBMEDToday
Researchers looked at how the FDA approves medicines for rare diseases from 2020 to 2024. They found that 129 rare disease drugs were approved during this time, and 25 of them (about 19%) used real-world data—information collected from patients outside of traditional clinical trials. Real-world data is becoming more important for rare diseases because it's often impossible to run large traditional studies when so few people have a disease.
WHY IT MATTERSIf you have a rare disease, this research shows the FDA is increasingly accepting real-world evidence from patient experiences and medical records to approve new treatments, which could mean faster access to medicines when traditional large-scale trials aren't feasible.
ResearchPUBMEDToday
Scientists are testing a new way to run drug trials for rare diseases where there aren't enough patients. Instead of only comparing patients at one specific time point, this method allows researchers to use patient information from multiple different dates. This could make it easier and faster to test new medicines for rare diseases without needing as many people in the study.
WHY IT MATTERSIf this method gets adopted by regulators, it could speed up approval timelines for rare disease treatments by allowing researchers to use more real-world patient data, potentially bringing new therapies to patients years sooner.
ResearchPUBMED2 days ago
Researchers in the Netherlands are creating a large database to collect information about small intestinal adenocarcinoma, a rare type of cancer that starts in the small intestine. They're gathering medical records, tumor samples, and patient feedback to better understand how this cancer develops and which treatments work best. This study is important because doctors currently don't have enough information to know the best way to treat this disease.
WHY IT MATTERSFor the first time, patients with small intestinal adenocarcinoma will have their disease studied systematically in a large prospective cohort, which could lead to treatment recommendations tailored specifically to this rare cancer instead of borrowed from other gastrointestinal cancers.